MicroRNA‑629 inhibition suppresses the viability and invasion of non‑small cell lung cancer cells by directly targeting RUNX3 Retraction in /10.3892/mmr.2023.12930

Zhuang,Bufeng; Cheng,Youshuang

doi:10.3892/mmr.2019.9990

MicroRNA‑629 inhibition suppresses the viability and invasion of non‑small cell lung cancer cells by directly targeting RUNX3

Retraction in: /10.3892/mmr.2023.12930

Authors:
- Bufeng Zhuang
- Youshuang Cheng
View Affiliations

Affiliations: Department of Thoracic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 201900, P.R. China
Published online on: February 27, 2019 https://doi.org/10.3892/mmr.2019.9990
Pages: 3933-3940

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dysregulated microRNAs (miRNAs/miRs) directly modulate the biological functions of non‑small cell lung cancer (NSCLC) cells and contribute to the initiation and progression of NSCLC; however, the specific roles and underlying mechanisms of the dysregulated miRNAs in NSCLC require further investigation. The present study reported that miRNA‑629‑5p (miR‑629) was upregulated in NSCLC tissues and cell lines. High miR‑629 expression levels were significantly associated with tumour size, clinical stage and lymph node metastasis in patients with NSCLC. Functional experiments indicated that miR‑629 inhibition suppressed the viability and invasion NSCLC cells in vitro. Furthermore, bioinformatics prediction, luciferase reporter assay, reverse transcription‑quantitative polymerase chain reaction and western blot analysis demonstrated that runt‑related transcription factor 3 (RUNX3) was a direct target gene of miR‑629 in NSCLC. Restoration of RUNX3 expression suppressed the effects of miR‑629 inhibition in NSCLC cells. Rescue experiments revealed that RUNX3 knockdown partially abrogated the effects of miR‑629 inhibition on NSCLC cells. In summary, miR‑629 directly targeted RUNX3 to inhibit the progression of NSCLC, suggesting that this miRNA may be considered as a diagnostic and therapeutic target for patients with NSCLC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Nascimento AV, Bousbaa H, Ferreira D and Sarmento B: Non-small cell lung carcinoma: An overview on targeted therapy. Curr Drug Targets. 16:1448–1463. 2015. View Article : Google Scholar : PubMed/NCBI
3	Holdenrieder S and Stieber P: New challenges for laboratory diagnostics in non-small cell lung cancer. Cancer Biomark. 6:119–121. 2010. View Article : Google Scholar : PubMed/NCBI
4	Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA, Diekemper R, Detterbeck FC and Arenberg DA: Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 143 (Suppl 5):e314S–e340S. 2013. View Article : Google Scholar : PubMed/NCBI
5	Ding X, Yang Y, Sun Y, Xu W, Su B and Zhou X: MicroRNA-585 acts as a tumor suppressor in non-small-cell lung cancer by targeting hSMG-1. Clin Transl Oncol. 19:546–552. 2017. View Article : Google Scholar : PubMed/NCBI
6	Liu X and Chen J: Advances in diagnosis and treatment and whole process management of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 37:1–4. 2015.(In Chinese). PubMed/NCBI
7	Rosell R and Karachaliou N: Lung cancer: Maintenance therapy and precision medicine in NSCLC. Nat Rev Clin Oncol. 10:549–550. 2013. View Article : Google Scholar : PubMed/NCBI
8	Schnabel PA and Junker K: Neuroendocrine tumors of the lungs. From small cell lung carcinoma to diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Pathologe. 35:557–564. 2014.(In German). View Article : Google Scholar : PubMed/NCBI
9	Li Z, Song Y, Liu L, Hou N, An X, Zhan D, Li Y, Zhou L, Li P, Yu L, et al: miR-199a impairs autophagy and induces cardiac hypertrophy through mTOR activation. Cell Death Differ. 24:1205–1213. 2017. View Article : Google Scholar : PubMed/NCBI
10	Mao M, Wu Z and Chen J: MicroRNA-187-5p suppresses cancer cell progression in non-small cell lung cancer (NSCLC) through down-regulation of CYP1B1. Biochem Biophys Res Commun. 478:649–655. 2016. View Article : Google Scholar : PubMed/NCBI
11	Moretti F, D'Antona P, Finardi E, Barbetta M, Dominioni L, Poli A, Gini E, Noonan DM, Imperatori A, Rotolo N, et al: Systematic review and critique of circulating miRNAs as biomarkers of stage I–II non-small cell lung cancer. Oncotarget. 8:94980–94996. 2017.PubMed/NCBI
12	Gompelmann D, Eberhardt R and Herth FJ: Advanced malignant lung disease: What the specialist can offer. Respiration. 82:111–123. 2011. View Article : Google Scholar : PubMed/NCBI
13	Friedman RC, Farh KK, Burge CB and Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
14	Donadeu FX, Schauer SN and Sontakke SD: Involvement of miRNAs in ovarian follicular and luteal development. J Endocrinol. 215:323–334. 2012. View Article : Google Scholar : PubMed/NCBI
15	Liwak U, Faye MD and Holcik M: Translation control in apoptosis. Exp Oncol. 34:218–230. 2012.PubMed/NCBI
16	Rutnam ZJ and Yang BB: The involvement of microRNAs in malignant transformation. Histol Histopathol. 27:1263–1270. 2012.PubMed/NCBI
17	Wang N and Zhang T: Down-regulation of microRNA-135 promotes sensitivity of non-small cell lung cancer to gefitinib by targeting TRIM16. Oncol Res. 26:1005–1014. 2018. View Article : Google Scholar : PubMed/NCBI
18	Jin JJ, Liu YH, Si JM, Ni R and Wang J: Overexpression of miR-1290 contributes to cell proliferation and invasion of non small cell lung cancer by targeting interferon regulatory factor 2. Int J Biochem Cell Biol. 95:113–120. 2018. View Article : Google Scholar : PubMed/NCBI
19	Gao X, Li S, Li W, Wang G, Zhao W, Han J, Diao C, Wang X and Zhang M: MicroRNA-539 suppresses tumor cell growth by targeting the WNT8B gene in non-small cell lung cancer. J Cell Biochem. 120:2017.
20	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
21	Wang J, Song C, Tang H, Zhang C, Tang J, Li X, Chen B and Xie X: miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. Breast Cancer Res. 19:722017. View Article : Google Scholar : PubMed/NCBI
22	Jingushi K, Ueda Y, Kitae K, Hase H, Egawa H, Ohshio I, Kawakami R, Kashiwagi Y, Tsukada Y, Kobayashi T, et al: miR-629 targets TRIM33 to promote TGFbeta/Smad signaling and metastatic phenotypes in ccRCC. Mol Cancer Res. 13:565–574. 2015. View Article : Google Scholar : PubMed/NCBI
23	Phuah NH, Azmi MN, Awang K and Nagoor NH: Suppression of microRNA-629 enhances sensitivity of cervical cancer cells to 1′S-1′-acetoxychavicol acetate via regulating RSU1. Onco Targets Ther. 10:1695–1705. 2017. View Article : Google Scholar : PubMed/NCBI
24	Hattori A, Takamochi K, Oh S and Suzuki K: New revisions and current issues in the eighth edition of the TNM classification for non-small cell lung cancer. Jpn J Clin Oncol. 49:3–11. 2019. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Araki K, Osaki M, Nagahama Y, Hiramatsu T, Nakamura H, Ohgi S and Ito H: Expression of RUNX3 protein in human lung adenocarcinoma: Implications for tumor progression and prognosis. Cancer Sci. 96:227–231. 2005. View Article : Google Scholar : PubMed/NCBI
27	Torshabi M, Faramarzi MA, Tabatabaei Yazdi M, Ostad SN and Gharemani MH: Runx3 expression inhibits proliferation and distinctly alters mRNA expression of bax in AGS and A549 cancer cells. Iran J Pharm Res. 10:355–361. 2011.PubMed/NCBI
28	Wang Y, Li Y, Wu B, Shi C and Li C: MicroRNA-661 promotes non-small cell lung cancer progression by directly targeting RUNX3. Mol Med Rep. 16:2113–2120. 2017. View Article : Google Scholar : PubMed/NCBI
29	Lee JM, Shin JO, Cho KW, Hosoya A, Cho SW, Lee YS, Ryoo HM, Bae SC and Jung HS: Runx3 is a crucial regulator of alveolar differentiation and lung tumorigenesis in mice. Differentiation. 81:261–268. 2011. View Article : Google Scholar : PubMed/NCBI
30	Lee KS, Lee YS, Lee JM, Ito K, Cinghu S, Kim JH, Jang JW, Li YH, Goh YM, Chi XZ, et al: Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer. Oncogene. 29:3349–3361. 2010. View Article : Google Scholar : PubMed/NCBI
31	Cortinovis D, Monica V, Pietrantonio F, Ceresoli GL, La Spina CM and Wannesson L: MicroRNAs in non-small cell lung cancer: Current status and future therapeutic promises. Curr Pharm Des. 20:3982–3990. 2014. View Article : Google Scholar : PubMed/NCBI
32	Boeri M, Pastorino U and Sozzi G: Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis. Cancer J. 18:268–274. 2012. View Article : Google Scholar : PubMed/NCBI
33	Vannini I, Fanini F and Fabbri M: MicroRNAs as lung cancer biomarkers and key players in lung carcinogenesis. Clin Biochem. 46:918–925. 2013. View Article : Google Scholar : PubMed/NCBI
34	Shao L, Shen Z, Qian H, Zhou S and Chen Y: Knockdown of miR-629 inhibits ovarian cancer malignant behaviors by targeting testis-specific Y-like protein 5. DNA Cell Biol. 36:1108–1116. 2017. View Article : Google Scholar : PubMed/NCBI
35	Yan H, Li Q, Wu J, Hu W, Jiang J, Shi L, Yang X, Zhu D, Ji M and Wu C: MiR-629 promotes human pancreatic cancer progression by targeting FOXO3. Cell Death Dis. 8:e31542017. View Article : Google Scholar : PubMed/NCBI